Literature DB >> 8953814

Effects of liver diseases on drug metabolism.

G Paintaud1, Y Bechtel, M P Brientini, J P Miguet, P R Bechtel.   

Abstract

Although the liver is the main site of drug metabolism, conflicting results have been reported on drug elimination during liver diseases. Drug metabolism may depend on histological changes in the liver (acute or chronic hepatitis, cirrhosis) but may also depend on their origin (viral, toxic or immunological). Drug metabolism is also influenced by the severity of liver dysfunction. Cytochrome P450 isozymes and conjugation pathways may be differently affected by these conditions, and specific probe drugs have to be used in order to study the effect of diseases on each enzyme of drug metabolism. Probe-based assays must be validated during disease, since the pharmacokinetics of the parent drug and/or of its metabolites may be altered. Because of these limitations, therapeutic drug monitoring may be the most reliable way to adjust drug dosing at present.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8953814

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  5 in total

Review 1.  Effects of liver disease on pharmacokinetics. An update.

Authors:  V Rodighiero
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 2.  Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.

Authors:  G K Dresser; J D Spence; D G Bailey
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

3.  Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases.

Authors:  Li-Qun Yang; Shen-Jing Li; Yun-Fei Cao; Xiao-Bo Man; Wei-Feng Yu; Hong-Yang Wang; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

Review 4.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

Review 5.  Pharmacology of morphine in obese patients: clinical implications.

Authors:  Célia Lloret Linares; Xavier Declèves; Jean Michel Oppert; Arnaud Basdevant; Karine Clement; Christophe Bardin; Jean Michel Scherrmann; Jean Pierre Lepine; Jean François Bergmann; Stéphane Mouly
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.